-
Mashup Score: 3Amplified Risk of Intracranial Artery Stenosis/Occlusion Associated With RNF213 p.R4810K in Familial Hypercholesterolemia: - 7 month(s) ago
Abstract Background The RNF213 p.R4810K variant is associated with moyamoya disease in East Asian individuals and increases the risk of developing intracranial major artery stenosis/occlusion (ICAS…
Source: www.jacc.orgCategories: Latest Headlines, Partners & KOLsTweet
-
Mashup Score: 13
We are grateful to these distinguished faculty who contributed to this collection: Michael D. Shapiro, DO, FACC (Chair) Charles German, MD, MS Christie M. Ballantyne, MD, FACC Pam Taub, MD, FACC Raul D. Santos MD, PhD, MSc Salim S. Virani, MD, FACC Sarah de Ferranti MD, MPH
Source: learn.acc.orgCategories: Cardiology News and Journals, Latest HeadlinesTweet-
Improve detection & diagnosis of #FH w/ the #FamilialHypercholesterolemia: Improving Detection to Accelerate Treatment 💻 course. Learn to identify & treat patients w/ this extremely high-risk condition w/ ACC's free online course. https://t.co/bPzupFYxpz #KnowFH #FHAwarenessDay https://t.co/c1eoyCCCSD
-
-
Mashup Score: 1
We are grateful to these distinguished faculty who contributed to this collection: Michael D. Shapiro, DO, FACC (Chair) Charles German, MD, MS Christie M. Ballantyne, MD, FACC Pam Taub, MD, FACC Raul D. Santos MD, PhD, MSc Salim S. Virani, MD, FACC Sarah de Ferranti MD, MPH
Source: learn.acc.orgCategories: Cardiology News and Journals, Latest HeadlinesTweet-
This #Cholesterol Education month, 🔎 ACC's 💻 course, #FamilialHypercholesterolemia: Improving Detection to Accelerate Treatment, which features an infographic, expert analysis, a three-part CardiaCast podcast series & quick-tip 📹. ➡️ https://t.co/bPzupFYxpz #KnowFH #ACCEd https://t.co/vt9YyUpRrh
-
-
Mashup Score: 0
Monthly lerodalcibep on top of maximum tolerated therapy reduced LDL an additional 60% over 24 weeks in patients with heterozygous familial hypercholesterolemia, with a safety profile similar vs. placebo, a speaker reported.The results of the global phase 3 LIBerate-HeFH trial were presented at the European Society of Cardiology Congress and simultaneously published in the European Heart Journal.
Source: www.healio.comCategories: Cardiology News and Journals, Latest HeadlinesTweet-
Monthly #lerodalcibep + maximum tolerated therapy reduced LDL an additional 60% over 24 weeks in patients with heterozygous #FamilialHypercholesterolemia, with a safety profile similar vs. placebo @EndocrineToday #ESCCongress @ESCardioNews #cardiotwitter https://t.co/f0RXINiLe1
-
-
Mashup Score: 0
For patients with familial hypercholesterolemia, overeating was connected to a lower quality of life, underscoring the need for a multidisciplinary approach when it comes to treating patients in this population, according to researchers.Considering that factors like family history, ethnicity and diet can all contribute to blood cholesterol levels, researchers have looked to unhealthy diets as a
Source: www.healio.comCategories: General Medicine News, Latest HeadlinesTweet-
🩺 For patients with #familialhypercholesterolemia, overeating was connected to a lower quality of life, according to the results of research published in @Nutrients_MDPI 🔗 Read more: https://t.co/ohRm22paBd
-
-
Mashup Score: 0Leverage blood donation system to uncover ‘underdiagnosed’ familial hypercholesterolemia - 9 month(s) ago
ARLINGTON, Texas — Familial hypercholesterolemia is common, underdiagnosed and undertreated, and one complementary approach to improve its diagnosis could include leveraging the blood donation system, according to a speaker. It is estimated that about one in 250 people have familial hypercholesterolemia (FH), an autosomal-dominant disorder that is common across race and ethnic groups and is
Source: www.healio.comCategories: Cardiology News and Journals, Latest HeadlinesTweet-
#FamilialHypercholesterolemia is common, underdiagnosed and undertreated, and one complementary approach to improve its diagnosis could include leveraging the blood donation system @dramitkhera @UTSWNews @ASPCardio #ASPC2023 https://t.co/OfzNEPr60O
-
-
Mashup Score: 2Xyleme Syndicate Portal - 10 month(s) ago
{{‘document.preview.not.available’ | i18n}} {{‘document.preview.open.in.new.window’ | i18n}} {{‘document.preview.click.in.new.window’ | i18n}} {{ coreErrorMessage ? coreErrorMessage : (‘share.preview.error.403’ | i18n) }} {{ coreErrorMessage ? coreErrorMessage : (‘share.preview.error.404’…
Source: acc.bravais.comCategories: Cardiology News and Journals, Latest HeadlinesTweet-
Watch a Quick Tip video on screening for #FH in children & adolescents! The video reviews which children should be screened for FH & when they should be screened. 📽️ https://t.co/qSFoFsNVxj #ACCEd #CardioTwitter #FamilialHypercholesterolemia #KnowFH https://t.co/AeRhDy7fmS
-
-
Mashup Score: 0
We are grateful to these distinguished faculty who contributed to this collection: Michael D. Shapiro, DO, FACC (Chair) Charles German, MD, MS Christie M. Ballantyne, MD, FACC Pam Taub, MD, FACC Raul D. Santos MD, PhD, MSc Salim S. Virani, MD, FACC Sarah de Ferranti MD, MPH
Source: learn.acc.orgCategories: Cardiology News and Journals, Latest HeadlinesTweet-
#FamilialHypercholesterolemia is the most common autosomal-dominant genetic disorder, affecting approximately 30 million patients 🌎. Find free, online #ACCEd on improving #FH detection & more. 🔎 https://t.co/bPzupFYxpz #KnowFH #CardioTwitter https://t.co/qosTrIAeJ1
-
-
Mashup Score: 0
Regeneron Pharmaceuticals announced the FDA has extended approval of evinacumab-dgnb as an adjunct to other lipid-lowering therapy for the treatment of homozygous familial hypercholesterolemia in children aged 5 to 11 years.After priority review by the FDA, evinacumab-dgnb (Evkeeza) is the first angiopoietin-like 3 inhibitor treatment to be indicated for children as young as 5 years old to treat
Source: www.healio.comCategories: Cardiology News and Journals, Latest HeadlinesTweet-
ICYMI: Regeneron announced the FDA has extended approval of #evinacumab-dgnb as an adjunct to other lipid-lowering therapy for the treatment of homozygous #FamilialHypercholesterolemia in children aged 5 to 11 years @US_FDA @EndocrineToday #Cardiotwitter https://t.co/Mloyd90aW3
-
-
Mashup Score: 0
Regeneron Pharmaceuticals announced the FDA has extended approval of evinacumab-dgnb as an adjunct to other lipid-lowering therapy for the treatment of homozygous familial hypercholesterolemia in children aged 5 to 11 years.After priority review by the FDA, evinacumab-dgnb (Evkeeza) is the first angiopoietin-like 3 inhibitor treatment to be indicated for children as young as 5 years old to treat
Source: www.healio.comCategories: Cardiology News and Journals, Latest HeadlinesTweet-
ICYMI: Regeneron announced the FDA has extended approval of #evinacumab-dgnb as an adjunct to other lipid-lowering therapy for the treatment of homozygous #FamilialHypercholesterolemia in children aged 5 to 11 years @US_FDA @EndocrineToday #Cardiotwitter https://t.co/Mloyd8ZD6v
-
#FamilialHypercholesterolemia pts exhibit ⬆️prevalence & severity of intracranial major artery stenosis/occlusion (ICASO) assoc w/ RNF213 p.R4810K. FH gene mutations may confer ⬆️risk of ICASO in RNF213 p.R4810K carriers. https://t.co/KsHxBeTg2Y #JACCAsia #ACCIntl #CardioTwitter https://t.co/wfUGDviDvA